Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the main therapeutic agents used to treat non–small-cell lung cancer patients harboring EGFR-activating mutations. However, most of these patients will eventually develop resistance, 50% of which are due to a secondary mut...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-01-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253116302918 |
id |
doaj-85465279870d4b9eb4e41fe38078fd2f |
---|---|
record_format |
Article |
spelling |
doaj-85465279870d4b9eb4e41fe38078fd2f2020-11-24T21:11:14ZengElsevierMolecular Therapy: Nucleic Acids2162-25312014-01-013C10.1038/mtna.2014.3Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzymeWei-Yun Lai0Chi-Yuan Chen1Shuenn-Chen Yang2Jer-Yuarn Wu3Cheng-Ju Chang4Pan-Chyr Yang5Konan Peck6Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, TaiwanDepartment of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the main therapeutic agents used to treat non–small-cell lung cancer patients harboring EGFR-activating mutations. However, most of these patients will eventually develop resistance, 50% of which are due to a secondary mutation at T790M in the EGFR. In this paper, we describe the development of an allele-specific DNAzyme, DzT, that can specifically silence EGFR T790M mutant messenger RNA while leaving wild-type EGFR intact. Allele-specific silencing of EGFR T790M expression and downstream signaling by DzT triggered apoptosis in non–small-cell lung cancer cells harboring this mutant. Adding a cholesterol-triethylene glycol group on the 3′-end of DzT (cDzT) improved drug efficacy, increasing inhibitory effect on cell viability from 46 to 79% in T790M/L858R-harboring H1975TM/LR non–small-cell lung cancer cells, without loss of allele specificity. Combined treatment with cDzT and BIBW-2992, a second-generation EGFR-tyrosine kinase inhibitor, synergistically inhibited EGFR downstream signaling and suppressed the growth of xenograft tumors derived from H1975TM/LR cells. Collectively, these results indicate that the allele-specific DNAzyme, DzT, may provide an alternative treatment for non–small-cell lung cancer that is capable of overcoming EGFR T790M mutant-based tyrosine kinase inhibitor resistance.http://www.sciencedirect.com/science/article/pii/S2162253116302918DNAzymeEGFR T790MNSCLCTKI |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wei-Yun Lai Chi-Yuan Chen Shuenn-Chen Yang Jer-Yuarn Wu Cheng-Ju Chang Pan-Chyr Yang Konan Peck |
spellingShingle |
Wei-Yun Lai Chi-Yuan Chen Shuenn-Chen Yang Jer-Yuarn Wu Cheng-Ju Chang Pan-Chyr Yang Konan Peck Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme Molecular Therapy: Nucleic Acids DNAzyme EGFR T790M NSCLC TKI |
author_facet |
Wei-Yun Lai Chi-Yuan Chen Shuenn-Chen Yang Jer-Yuarn Wu Cheng-Ju Chang Pan-Chyr Yang Konan Peck |
author_sort |
Wei-Yun Lai |
title |
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme |
title_short |
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme |
title_full |
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme |
title_fullStr |
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme |
title_full_unstemmed |
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme |
title_sort |
overcoming egfr t790m-based tyrosine kinase inhibitor resistance with an allele-specific dnazyme |
publisher |
Elsevier |
series |
Molecular Therapy: Nucleic Acids |
issn |
2162-2531 |
publishDate |
2014-01-01 |
description |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the main therapeutic agents used to treat non–small-cell lung cancer patients harboring EGFR-activating mutations. However, most of these patients will eventually develop resistance, 50% of which are due to a secondary mutation at T790M in the EGFR. In this paper, we describe the development of an allele-specific DNAzyme, DzT, that can specifically silence EGFR T790M mutant messenger RNA while leaving wild-type EGFR intact. Allele-specific silencing of EGFR T790M expression and downstream signaling by DzT triggered apoptosis in non–small-cell lung cancer cells harboring this mutant. Adding a cholesterol-triethylene glycol group on the 3′-end of DzT (cDzT) improved drug efficacy, increasing inhibitory effect on cell viability from 46 to 79% in T790M/L858R-harboring H1975TM/LR non–small-cell lung cancer cells, without loss of allele specificity. Combined treatment with cDzT and BIBW-2992, a second-generation EGFR-tyrosine kinase inhibitor, synergistically inhibited EGFR downstream signaling and suppressed the growth of xenograft tumors derived from H1975TM/LR cells. Collectively, these results indicate that the allele-specific DNAzyme, DzT, may provide an alternative treatment for non–small-cell lung cancer that is capable of overcoming EGFR T790M mutant-based tyrosine kinase inhibitor resistance. |
topic |
DNAzyme EGFR T790M NSCLC TKI |
url |
http://www.sciencedirect.com/science/article/pii/S2162253116302918 |
work_keys_str_mv |
AT weiyunlai overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme AT chiyuanchen overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme AT shuennchenyang overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme AT jeryuarnwu overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme AT chengjuchang overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme AT panchyryang overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme AT konanpeck overcomingegfrt790mbasedtyrosinekinaseinhibitorresistancewithanallelespecificdnazyme |
_version_ |
1716754061526564864 |